Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Novel Conditioning Regimen Shows Benefit for Beta-Thalassemia Major

Key clinical point: A novel transplant protocol improved survival outcomes and rates of graft-versus-host disease (GVHD) in patients with beta-thalassemia major undergoing unrelated-donor hematopoietic stem cell transplant (HSCT).

Major finding: The rates of thalassemia-free and overall survival were both 100%, while the incidence rates of acute (grade 2-4) and chronic GVHD were both 8.3%.

Study details: A single-center cohort study of 48 patients with beta-thalassemia major.

Disclosures: The study was funded by the Public Welfare Science and Technology Project of Wenzhou, the Natural Science Foundation of Zhejiang Province, and the National Natural Science Foundation of China. The authors reported having no conflicts of interest.